Tissue factor-fVIIa inhibition: update on an unfinished quest for a novel oral antithrombotic

E Scott Priestley

doi:10.1016/j.drudis.2014.05.023

Tissue factor-fVIIa inhibition: update on an unfinished quest for a novel oral antithrombotic

Drug Discov Today. 2014 Sep;19(9):1440-4. doi: 10.1016/j.drudis.2014.05.023. Epub 2014 May 29.

Author

E Scott Priestley¹

Affiliation

¹ Bristol-Myers Squibb Research, 311 Pennington-Rocky-Hill Road, Pennington, NJ 08534, USA. Electronic address: [email protected].

PMID: 24881783
DOI: 10.1016/j.drudis.2014.05.023

Abstract

The tissue factor-coagulation factor VIIa complex (TF-fVIIa) is a well-validated biological target and has been the focus of extensive research directed toward the discovery of novel oral antithrombotics. This review briefly summarizes the key antithrombotic target validation data and provides an update on recent advances in small molecule TF-fVIIa inhibitors.

Publication types

Review

MeSH terms

Administration, Oral
Animals
Drug Design
Factor VIIa / antagonists & inhibitors*
Fibrinolytic Agents / administration & dosage
Fibrinolytic Agents / pharmacology*
Humans
Thromboplastin / antagonists & inhibitors*

Substances

Fibrinolytic Agents
Thromboplastin
Factor VIIa